Unnatural Products Announces Multi-Target Collaboration with argenx to Develop Oral Macrocyclic Peptide Therapeutics
– UNP to receive a double digit million dollar upfront payment, near-term payments and up to approximately $1.5B in potential milestone payments plus royalties – Partnership will harness UNP's AI enhanced macrocycle platform to drug historically “undruggable” targets SANTA CRUZ, Calif., July 01, 2025 (GLOBE NEWSWIRE) — Unnatural Products, Inc. (UNP), a biotech developing orally-delivered […]